This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Abbott Labs: Balancing Growth and Profits

Stock quotes in this article: ABT, ABBV, JNJ, MDT

NEW YORK ( TheStreet) -- It's now been two full quarters since healthcare conglomerate Abbott Laboratories (ABT) effectively separated itself from its drug business -- spinning off that segment into a new entity called AbbVie (ABBV).

The spin-off, which was originally announced in late 2011, was a long-anticipated move, for which Abbott investors cheered. It came with plenty of expectations that the remaining portion of Abbott, which consists of the devices business, would post stronger growth results. But since the separation took effect in January of this year, questions have been raised as to which of the two companies presents the better value.

Shares of AbbVie, which have soared more than 30% on the year, have been one of the best performers within the sector. Abbott, meanwhile, has posted gains of 16%. It's not a terrible performance, but the stock has lagged behind Johnson & Johnson (JNJ) and Medtronic (MDT). Although second-quarter earnings results were better than expected, I didn't see enough to buy shares of Abbott today with my own money.

As with the April quarter, revenue growth, which registered at just 2% year over year, was another struggle. Even when adjusting for currency exchange rates, which pushes Abbott's growth rate to 4%, the company still missed estimates. By contrast, it pales in comparison to Johnson & Johnson, which recently posted year-over-year growth of 10%.

As with Johnson & Johnson, which has come to rely heavily on its drugs business, it is Abbott's nutrition business, which now accounts for 31% of the company's revenue, that continues to do all of the heavily lifting. Nutrition was up 8% year-over year. It's starting to appear as if Abbott's international expansion plans are paying dividends.

Management said the strong performance was due to geographic development programs that it projected would have spurred these type of results. In that regard, investors should be encouraged that revenue in both pediatric and adult products are growing better-than-expected at a high-single-digit pace.

To what degree this performance can continue remains to be seen. But for now, I'm not willing to bet against management's plan to achieve 20% operating margin in nutrition over the next two years. Unfortunately, though, this is the extent of the positives that I could draw from the quarter. Outside of the 8% increase in the diagnostics business, I was disappointed by Abbott's performance in its other businesses.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,760.97 -43.74 -0.26%
S&P 500 1,932.91 -13.25 -0.68%
NASDAQ 4,390.5780 -31.5070 -0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs